BIOVERATIV US LLC

BIOVERATIV US LLC specializes in advanced biopharmaceutical research and development services, with a focus on process development, analytical characterization, and regulatory-compliant manufacturing support for complex therapeutic modalities. Leveraging deep expertise in biologics lifecycle management, the company delivers technical solutions spanning upstream and downstream process optimization, protein purification, analytical method validation, and quality control systems aligned with cGMP and FDA guidelines. Their technical capabilities include chromatographic separation technologies, mass spectrometry, spectroscopic analysis, and bioanalytical assay development, with an emphasis on ensuring product purity, stability, and batch consistency for clinical and commercial applications. The organization distinguishes itself through its rigorous adherence to scientific integrity and regulatory frameworks, enabling seamless transition of biologics from lab-scale innovation to validated production environments. Award history is not available to confirm specific agency engagements, so no definitive patterns of federal client relationships can be inferred. Similarly, without contract data, primary NAICS categorization cannot be validated beyond the primary code 541714, which corresponds to research and development in the physical, engineering, and life sciences—indicating a focus on scientific R&D rather than broad-based IT or infrastructure services. BIOVERATIV US LLC operates as a limited liability entity headquartered in Waltham, Massachusetts, positioning it within a major biopharma innovation corridor. The company holds no government certifications, and its market presence is grounded in scientific expertise rather than formal socioeconomic program participation. Its geographic location supports collaboration with academic institutions, biotech firms, and pharmaceutical partners in the greater Boston area, reinforcing its role as a specialized technical services provider in the life sciences sector.